Investigational drug · Phase 3
Rovadicitinib
Also called: TQ05105
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Graft Versus Host Disease, Myelofibrosis, Graft-versus-host Disease.
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
3
Any phase or sponsor naming "Rovadicitinib"
First trial start
2021
Jun 25, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Rovadicitinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Graft Versus Host Disease
- Myelofibrosis
- Graft-versus-host Disease
Approved drugs for the same conditions: Myelofibrosis · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Rovadicitinib" as an intervention, largest first.
- Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host DiseasePivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06682169 · 182 participants (planned) · Start Nov 20, 2024 · Primary completion Oct 2029
Drug: Rovadicitinib; Imatinib and 3 more · For: Graft-versus-host Disease
Sites: Hefei, China; Beijing, China; Chongqing, China · 41 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06300320 · 65 participants (planned) · Start May 7, 2024 · Primary completion Nov 2027
Drug: TQ05105 tablets · For: Chronic Graft Versus Host Disease
Sites: Hefei, China; Lanzhou, China; Guangzhou, China · 12 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07551427 · 51 participants (planned) · Start Jun 18, 2026 · Primary completion Jun 2028
Drug: TQ05105 Tablets (Rovadicitinib Tablets) · For: Myelofibrosis
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 24 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Rovadicitinib: First Approval.
Blair HA · Drugs 2026
- Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study.
Xu Z, Liu J, Hong Z, et al. · Blood Cancer J 2026
- Chronic graft-versus-host disease.
Ye Y, Savani B, Malard F, et al. · Nat Rev Dis Primers 2026
- Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?
Jamil MA, Otoukesh S, Ali H · Expert Opin Investig Drugs 2026
- Optimal Treatment of Steroid-refractory Chronic Graft-versus-host Disease (cGvHD) in the Era of Novel drugs - a Systematic Review and Meta-analysis.
Karaszewski K, Sekua M, Jwdrzejczak WW · Stem Cell Rev Rep 2026
- New molecules in the therapy of chronic graft-versus-host disease.
Steiner L, Klein SA, Kreil S · Curr Opin Hematol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.